A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Adjuvanted R21 at Two Different Doses and the Combination Malaria Vaccine Candidate Regimen of Adjuvanted R21 + ChAd63 and MVA Encoding ME-TRAP

Trial Profile

A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Adjuvanted R21 at Two Different Doses and the Combination Malaria Vaccine Candidate Regimen of Adjuvanted R21 + ChAd63 and MVA Encoding ME-TRAP

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ME-TRAP malaria DNA vaccine Okairos (Primary) ; R 21 (Primary) ; Adjuvants; Antihistamines; Artemether/lumefantrine; Cyclizine; Paracetamol
  • Indications Malaria
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2018.
    • 03 Jul 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
    • 02 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top